News
Novartis’ heart failure med Entresto scores an expanded approval in the US
Novartis’ Entresto has been approved by the US Food and Drug Administration (FDA) for an expanded indication in chronic heart failure.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Novartis’ Entresto has been approved by the US Food and Drug Administration (FDA) for an expanded indication in chronic heart failure.